Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 9, 2020

MediciNova to study ibudilast for Covid-19-related ARDS

Biopharmaceutical company MediciNova has plans to study its investigational drug, ibudilast (MN-166), to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.

Biopharmaceutical company MediciNova has plans to study its investigational drug, ibudilast (MN-166), to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.

Ibudilast is an oral, small-molecule inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE) -4 and -10. It inhibits pro-inflammatory cytokines and promotes neurotrophic factors.

In previous studies, the drug candidate led to a significant decrease in serum MIF level.

The company also added that ibudilast showed anti-neuroinflammatory and neuroprotective properties in preclinical and clinical studies for neurological diseases, including amyotrophic lateral sclerosis and progressive multiple sclerosis.

MediciNova president and CEO Yuichi Iwaki said: “We are very pleased to announce initiation of a clinical trial of MN-166 in ARDS caused by Covid-19.

“This study also will allow investigators to determine the optimal dose and route of administration in these very critical patients.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

MediciNova expects that the drug candidate could mitigate the hyper-inflammation and ARDS found in severe cases of Covid-19 infection.

The planned study of ibudilast in Covid-19 patients will be performed by Yale’s Advanced Therapies Group.

Yale’s Advanced Therapies Group co-director Richard Bucala said: “This study is especially gratifying because MN-166’s inhibition of MIF activity was discovered in Yale Pharmacology by Elias Lolis.

“We believe MN-166 has the potential to reduce the mortality of Covid-19 by limiting the hyper-inflammation and ARDS associated with severe cases.”

In a separate development, Yale University said that its lung fibrosis drug candidate sobetirome may possess the potential to treat some life-threatening effects of Covid-19.

Sobetirome works by healing scarring and improving cell function in lungs. In a recent study, the drug also demonstrated promise in preventing and treating ARDS.

Researchers at the university are making preparations to study sobetirome in trials.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU